Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ivim Health vs LunaRx

Ivim Health
Graded #338

Lower grade

vs+1.6000000000000014
LunaRx
Graded #299

Higher grade

The verdict

LunaRx takes it — 61.2/100 to 59.6/100, but only just.

LunaRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LunaRx is a bilingual (English/Spanish) telehealth practice from LunaRx LLC built around "metabolic recomposition" — compounded GLP-1 therapy paired with muscle-protective peptides and a structured off-ramp… Ivim Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLunaRx +10
44
54
Dose & formulationIvim Health +12
64
52
Clinical oversightLunaRx +3
79
82
Labs & monitoringLunaRx +2
52
54
FulfillmentLunaRx +5
65
70
Contract termsEven
55
55
Ivim Health · left barLunaRx · right bar

The numbers

MetricIvim HealthLunaRx
WeighScore59.6/10061.2/100
GradeCC
Scorecard rank#338#299
Semaglutide$149/mo (starting dose, medication and programme fee, compounded)$199/mo (starting dose, compounded)
Tirzepatide$224/mo (starting dose, medication and programme fee, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Ivim Health

Graded #338 · C

Strengths

  • Both molecules are priced on one page, each quoted as medication and programme charge included rather than as a bare drug price
  • A six-month commitment brings tirzepatide down to $133/mo, and the term is published rather than hidden
  • The first month of the membership is free

Where it loses points

  • A $75/mo membership is marketed as a separate product, and whether it is charged on top of the $149 medication rate is not stated anywhere we could find
  • The $133/mo tirzepatide rate advertised on the homepage requires a six-month commitment; the month-to-month rate is $224
  • Both figures are 'starting at' rates, so the cost of a titrated dose is not published
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
LunaRx

Graded #299 · C

Strengths

  • Pairs GLP-1 with muscle-protective peptides (e.g., CJC-1295/Ipamorelin, NAD+) to defend lean mass during fat loss
  • Structured, physician-directed off-ramp taper with GI-reset support instead of an indefinite prescription
  • Bilingual care in English and Spanish across intake, messaging, and consults
  • Care directed through a named independent medical group (CareNexus Clinic PC); $0 charged if you are not approved
  • Published clinical support hours (Mon–Fri, CT) with phone, email, and secure messaging; cancel anytime

Where it loses points

  • Only a "from $199/mo" starting price is published; tirzepatide and per-tier pricing are confirmed only after a provider review
  • Compounding pharmacy partners are not named on the site — a transparency gap
  • No LegitScript or PCAB verification is displayed
  • States served are not published; the site claims "telehealth nationwide" but the Terms limit service to states where LunaRx is licensed
  • Compounded medications are not FDA-approved (the site discloses this)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard